Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2022-03-08 Director's Dealing
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-03-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-08 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Sutro Biopharma, Inc. It registers additional shares under the company's Equity Incentive Plan and Employee Stock Purchase Plan. The document includes legal and procedural information related to securities registration, including consents, powers of attorney, and incorporation by reference to other filings. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration and capital changes. Form S-8 is specifically used for registering securities to be offered to employees under benefit plans, which aligns with announcements of share issuance or capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a mere announcement but a full registration statement.
2022-03-01 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Registration Statement on Form S-3 filed with the SEC by Sutro Biopharma, Inc. It is a shelf registration statement allowing the company to offer securities up to $350 million. The text includes detailed descriptions of the securities, the registration process, and disclaimers typical of a registration statement. There are no financial statements or earnings data, nor is this a report of financial results or management discussion. It is clearly a capital raising and securities registration filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2022-02-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.